Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.69−0.02 (-3.12%)
Close on Nov 13, 2026Market cap $26.13MP/E –Yield –
Metagenomi Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Metagenomi Therapeutics's total assets was $157.39M at Sep 30, 2026. For fiscal 2025 it was $221.10M, down 31.9% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.10M | -31.9% |
| FY2024 | Dec 31, 2024 | $324.60M | -11.0% |
| FY2023 | Dec 31, 2023 | $364.84M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $157.39M | -36.5% |
| Q2 FY2026 | Jun 30, 2026 | $173.70M | -36.2% |
| Q1 FY2026 | Mar 31, 2026 | $196.95M | -33.9% |
| Q4 FY2025 | Dec 31, 2025 | $221.10M | -31.9% |
| Q3 FY2025 | Sep 30, 2025 | $247.94M | -30.8% |
| Q2 FY2025 | Jun 30, 2025 | $272.28M | -29.4% |
| Q1 FY2025 | Mar 31, 2025 | $297.87M | -28.3% |
| Q4 FY2024 | Dec 31, 2024 | $324.60M | -11.0% |
| Q3 FY2024 | Sep 30, 2024 | $358.35M | – |
| Q2 FY2024 | Jun 30, 2024 | $385.91M | – |
| Q1 FY2024 | Mar 31, 2024 | $415.40M | – |
| Q4 FY2023 | Dec 31, 2023 | $364.84M | – |
See a number that looks wrong?